Biotech Convergence: Human Trials Show "Senolytic" Anti-Aging Drugs Improve Uterine Receptivity

Longevity
Written By camellia chen

  • 【Abstract】: (R&D Breakthrough) A groundbreaking Phase II clinical trial published in Nature Aging demonstrates that administering Senolytic drugs (which clear out toxic, "zombie" senescent cells) prior to an IVF cycle significantly reduces uterine inflammation and improves embryo implantation rates in women over 40.

  • Business Insight: The silos between "Anti-Aging" and "Reproduction" are collapsing. "Pre-IVF Longevity Protocols" will become the new standard of care for older patients. Clinics should begin partnering with longevity physicians to offer comprehensive "Cellular Cleansing" programs as a high-margin preparatory phase before starting expensive IVF stimulation.

  • 【Keywords】: #Senolytics #AntiAging #FertilityOptimization

  • 【Source】: Nature Aging / Longevity Technology (Feb 23, 2026)

camellia chen
Previous

Global Exosome Therapy Market to Reach $2.5 Billion by 2030, Driven by Aesthetics and Longevity
Next

Merck Acquires Chinese AI Follicle Tracking Startup to Enhance Digital Fertility Ecosystem